Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Othera Pharmaceuticals, a specialty pharmaceuticals company, has received a new patent from the US Patent and Trademark Office that covers a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation pathways believed to be involved in age-related macular degeneration and other diseases of the eye.
Subscribe to our email newsletter
The new patent covers several new chemical entities, including composition of matter and use of the company’s lead product candidate, OT-551. With anticipated patent life extensions, the patent is expected to be valid through at least 2024.
OT-551 is a topically-dosed, novel small molecule that inhibits oxidative stress and disease-induced inflammation. The company has completed enrollment of a Phase II clinical trial of OT-551 for the treatment of an advanced form of dry age-related macular degeneration, also termed geographic atrophy (GA).
In preclinical studies of retinal disease, OT-551 has been shown to reach the back of the eye in efficacious amounts after topical dosing, and has demonstrated excellent safety to date, providing the key rationale for studying the drug in patients with GA.
David Joseph, Othera’s chairman and CEO, said: “We are quite pleased that the USPTO has issued this important patent to protect our OT-551 intellectual property estate.”